C4 Therapeutics (CCCC)

C4 Therapeutics Stock Analysis & Ratings

CCCC Stock Chart & Stats

Day’s Range$6.28 - $6.98
52-Week Range$6.20 - $51.21
Previous Close$6.61
Average Volume (3M)858.71K
Market Cap$325.48M
P/E Ratio-3.3
Next EarningsAug 10, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score2
EPS (TTM)-1.99



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $6.20 and its highest was $51.21 in the past 12 months.
    What is C4 Therapeutics’s market cap?
    C4 Therapeutics’s market cap is $325.48M.
      What is C4 Therapeutics’s price target?
      The average price target for C4 Therapeutics is $30.40. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $84.00 ,the lowest forecast is $10.00. The average price target represents 355.77% Increase from the current price of $6.67.
        What do analysts say about C4 Therapeutics?
        C4 Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
          When is C4 Therapeutics’s upcoming earnings report date?
          C4 Therapeutics’s upcoming earnings report date is Aug 10, 2022 which is in 79 days.
            How were C4 Therapeutics’s earnings last quarter?
            C4 Therapeutics released its earnings results on May 05, 2022. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.618 by -$0.032.
              Is C4 Therapeutics overvalued?
              According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
                Does C4 Therapeutics pay dividends?
                C4 Therapeutics does not currently pay dividends.
                What is C4 Therapeutics’s EPS estimate?
                C4 Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does C4 Therapeutics have?
                C4 Therapeutics has 48,800,000 shares outstanding.
                  What happened to C4 Therapeutics’s price movement after its last earnings report?
                  C4 Therapeutics reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.618. Following the earnings report the stock price went down -4.035%.
                    Which hedge fund is a major shareholder of C4 Therapeutics?
                    Among the largest hedge funds holding C4 Therapeutics’s share is Perceptive Advisors LLC. It holds C4 Therapeutics’s shares valued at 51M.


                      C4 Therapeutics Stock Analysis

                      Smart Score
                      Price Target
                      ▲(355.77% Upside)
                      Moderate Buy
                      The C4 Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      C4 Therapeutics

                      C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis